IR-Med

IR-Med EBITDA per Share

The EBITDA per Share of IR-Med (IRME) as of Nov 5, 2026 is -0.03 USD. In the previous year, EBITDA per Share was -0.07 USD — a change of -61.36% (higher).

EBITDA per Share

-0.03USD

YoY

-61.36%

Last updated:

EBITDA per Share of IR-Med is 2024 -0.03 USD. EBITDA per Share of IR-Med was 2023 -0.07 USD. It decreases by -61.36% higher compared to the previous year.

The IR-Med EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2020
-0.01 USD
Jan 1, 2021
-0.06 USD
Jan 1, 2022
-0.07 USD
Jan 1, 2023
-0.07 USD
Jan 1, 2024
-0.03 USD
The IR-Med EBITDA per Share history
YEAREBITDA per ShareYoY
-0.03USD-61.36%
-0.07USD+1.34%
-0.07USD+21.57%
-0.06USD+403.43%
-0.01USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IR-Med Stock analysis

What does IR-Med do? IR-Med, Inc. develops non-invasive medical devices using Infra-Red (IR) and Artificial Intelligence (AI) technologies. The company focuses on two principal products: PressureSafe, a handheld optical monitoring device for early detection of pressure injuries, and Nobiotics, an otoscope providing immediate indications for medical conditions. Healthcare professionals purchase these devices to detect biomarkers and molecules in real-time without invasive procedures. The company's initial product candidates are in various development stages, targeting medical indications requiring non-invasive diagnostics. IR-Med, Inc. generates revenue through the sale of PressureSafe and Nobiotics to healthcare providers. The devices are designed for specific medical applications, with PressureSafe addressing pressure injuries in bedridden patients and Nobiotics supporting physicians in otoscopic examinations. The company's business model centers on developing and commercializing these AI-enhanced medical devices to meet unmet diagnostic needs in healthcare settings. The firm's products are developed for real-time detection of biomarkers in blood and tissue, eliminating the need for invasive procedures. PressureSafe targets healthcare professionals managing bedridden patients, while Nobiotics serves physicians requiring immediate diagnostic insights during examinations. IR-Med, Inc. monetizes its technology through direct sales of these specialized medical devices to healthcare institutions and practitioners. IR-Med is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IR-Med stock

EBITDA per Share of IR-Med is -0.03 USD in 2024.

EBITDA per Share of IR-Med changed from -0.07 USD to -0.03 USD, representing a -61.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share IR-Med since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — IR-Med

All Key Metrics — IR-Med